| 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| 胞磷胆碱钠片(元) | 348,322,905.89 | 163,623,852.45 | 394,514,798.22 | 186,119,990.05 |
| 东方胃药胶囊(元) | 8,564,215.39 | 4,506,879.08 | 9,000,662.00 | 4,903,937.48 |
| 阿咖酚散(元) | 9,561,170.04 | 5,107,535.50 | 7,654,874.28 | 3,550,789.65 |
| 人工牛黄(元) | - | - | 5,152,300.92 | - |
| 苯甲酸利扎曲普坦胶囊(元) | 5,613,305.96 | 2,633,444.24 | - | - |
| 多酶片(元) | - | 2,266,879.38 | - | - |
| 酚氨咖敏片(元) | 9,800,164.52 | 6,520,969.81 | - | - |
| 普瑞巴林口服溶液(元) | 4,641,931.61 | 2,868,203.67 | - | - |
| 其他主营业务(元) | - | - | - | 3,550,789.65 |
| 其他药品(元) | - | - | - | 8,504,947.43 |
| 其他业务(元) | - | - | - | 265,586.85 |
| 其他品种(元) | 21,013,402.61 | 8,070,207.69 | 25,287,197.70 | 8,504,947.43 |
| 营业成本(元) | ||||
| 胞磷胆碱钠片(元) | 45,463,775.88 | 21,172,337.89 | 56,039,180.35 | 26,368,887.86 |
| 东方胃药胶囊(元) | 2,340,925.89 | 1,287,826.95 | 3,460,441.80 | 1,718,402.12 |
| 阿咖酚散(元) | 8,158,511.77 | 4,414,160.95 | 6,618,648.05 | 3,051,081.52 |
| 人工牛黄(元) | - | - | 4,847,023.03 | - |
| 苯甲酸利扎曲普坦胶囊(元) | 1,231,897.45 | 346,241.05 | - | - |
| 多酶片(元) | - | 1,039,755.69 | - | - |
| 酚氨咖敏片(元) | 6,406,176.88 | 3,922,437.18 | - | - |
| 普瑞巴林口服溶液(元) | 1,052,053.73 | 857,017.93 | - | - |
| 其他主营业务(元) | - | - | - | 3,051,081.52 |
| 其他药品(元) | - | - | - | 7,027,921.40 |
| 其他业务(元) | - | - | - | 208,985.10 |
| 其他品种(元) | 12,697,735.08 | 5,405,630.31 | 17,182,383.72 | 7,027,921.40 |
| 毛利(元) | ||||
| 胞磷胆碱钠片(元) | 302,859,130.01 | 142,451,514.56 | 338,475,617.87 | 159,751,102.19 |
| 东方胃药胶囊(元) | 6,223,289.50 | 3,219,052.13 | 5,540,220.20 | 3,185,535.36 |
| 阿咖酚散(元) | 1,402,658.27 | 693,374.55 | 1,036,226.23 | 499,708.13 |
| 人工牛黄(元) | - | - | 305,277.89 | - |
| 苯甲酸利扎曲普坦胶囊(元) | 4,381,408.51 | 2,287,203.19 | - | - |
| 多酶片(元) | - | 1,227,123.69 | - | - |
| 酚氨咖敏片(元) | 3,393,987.64 | 2,598,532.63 | - | - |
| 普瑞巴林口服溶液(元) | 3,589,877.88 | 2,011,185.74 | - | - |
| 其他主营业务(元) | - | - | - | 499,708.13 |
| 其他药品(元) | - | - | - | 1,477,026.03 |
| 其他业务(元) | - | - | - | 56,601.75 |
| 其他品种(元) | 8,315,667.53 | 2,664,577.38 | 8,104,813.98 | 1,477,026.03 |
| 毛利率(%) | ||||
| 胞磷胆碱钠片(%) | 86.95 | 87.06 | 85.80 | 85.83 |
| 东方胃药胶囊(%) | 72.67 | 71.43 | 61.55 | 64.96 |
| 阿咖酚散(%) | 14.67 | 13.58 | 13.54 | 14.07 |
| 人工牛黄(%) | - | - | 5.93 | - |
| 苯甲酸利扎曲普坦胶囊(%) | 78.05 | 86.85 | - | - |
| 多酶片(%) | - | 54.13 | - | - |
| 酚氨咖敏片(%) | 34.63 | 39.85 | - | - |
| 普瑞巴林口服溶液(%) | 77.34 | 70.12 | - | - |
| 其他主营业务(%) | - | - | - | 14.07 |
| 其他药品(%) | - | - | - | 17.37 |
| 其他业务(%) | - | - | - | 21.31 |
| 其他品种(%) | 39.57 | 33.02 | 32.05 | 17.37 |
| 收入构成(%) | ||||
| 胞磷胆碱钠片(%) | 85.47 | 83.65 | 89.34 | 86.41 |
| 东方胃药胶囊(%) | 2.10 | 2.30 | 2.04 | 2.28 |
| 阿咖酚散(%) | 2.35 | 2.61 | 1.73 | 1.65 |
| 人工牛黄(%) | - | - | 1.17 | - |
| 苯甲酸利扎曲普坦胶囊(%) | 1.38 | 1.35 | - | - |
| 多酶片(%) | - | 1.16 | - | - |
| 酚氨咖敏片(%) | 2.40 | 3.33 | - | - |
| 普瑞巴林口服溶液(%) | 1.14 | 1.47 | - | - |
| 其他主营业务(%) | - | - | - | 1.65 |
| 其他药品(%) | - | - | - | 3.95 |
| 其他业务(%) | - | - | - | 0.12 |
| 其他品种(%) | 5.16 | 4.13 | 5.73 | 3.95 |
| 毛利构成(%) | ||||
| 胞磷胆碱钠片(%) | 91.73 | 90.65 | 95.76 | 95.69 |
| 东方胃药胶囊(%) | 1.88 | 2.05 | 1.57 | 1.91 |
| 阿咖酚散(%) | 0.42 | 0.44 | 0.29 | 0.30 |
| 人工牛黄(%) | - | - | 0.09 | - |
| 苯甲酸利扎曲普坦胶囊(%) | 1.33 | 1.46 | - | - |
| 多酶片(%) | - | 0.78 | - | - |
| 酚氨咖敏片(%) | 1.03 | 1.65 | - | - |
| 普瑞巴林口服溶液(%) | 1.09 | 1.28 | - | - |
| 其他主营业务(%) | - | - | - | 0.30 |
| 其他药品(%) | - | - | - | 0.88 |
| 其他业务(%) | - | - | - | 0.03 |
| 其他品种(%) | 2.52 | 1.70 | 2.29 | 0.88 |